Ivan Mambule

1.2k total citations · 1 hit paper
22 papers, 213 citations indexed

About

Ivan Mambule is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ivan Mambule has authored 22 papers receiving a total of 213 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 7 papers in Virology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ivan Mambule's work include HIV/AIDS Research and Interventions (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV Research and Treatment (7 papers). Ivan Mambule is often cited by papers focused on HIV/AIDS Research and Interventions (9 papers), HIV/AIDS drug development and treatment (9 papers) and HIV Research and Treatment (7 papers). Ivan Mambule collaborates with scholars based in United Kingdom, Uganda and United States. Ivan Mambule's co-authors include Charles F. Gilks, Cissy Kityo, Andrew Reid, Diana M. Gibb, A. Sarah Walker, Peter Mugyenyi, Jonathan Levin, Sylvia Kiwuwa-Muyingo, Francis Ssali and Wolfgang Stöhr and has published in prestigious journals such as Nature Medicine, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Ivan Mambule

20 papers receiving 210 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

2024 47 citations Cissy Kityo, Ivan Mambule et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ivan Mambule United Kingdom	10	150	91	66	32	31	22	213
Jean-Marc Chapplain France	10	156 1.0×	92 1.0×	59 0.9×	27 0.8×	40 1.3×	16	231
Betsy Smith United States	7	173 1.2×	101 1.1×	68 1.0×	42 1.3×	39 1.3×	11	218
Shalton Mwaringa United Kingdom	6	143 1.0×	123 1.4×	46 0.7×	13 0.4×	15 0.5×	7	182
Herry Mapesi Tanzania	9	139 0.9×	49 0.5×	80 1.2×	16 0.5×	45 1.5×	23	198
T. R. Sterling United States	7	141 0.9×	64 0.7×	66 1.0×	14 0.4×	47 1.5×	10	187
G. Marasca Italy	9	95 0.6×	32 0.4×	83 1.3×	30 0.9×	24 0.8×	13	191
Antonio Antela Spain	8	300 2.0×	214 2.4×	57 0.9×	11 0.3×	98 3.2×	22	353
Charity Alfredo Mozambique	7	189 1.3×	77 0.8×	105 1.6×	43 1.3×	22 0.7×	7	213
Amy E. Colson United States	8	296 2.0×	180 2.0×	61 0.9×	17 0.5×	64 2.1×	17	348
Mitch Matoga United States	9	113 0.8×	24 0.3×	78 1.2×	21 0.7×	35 1.1×	40	224

Countries citing papers authored by Ivan Mambule

Since Specialization

Citations

This map shows the geographic impact of Ivan Mambule's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Mambule with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Mambule more than expected).

Fields of papers citing papers by Ivan Mambule

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Mambule. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Mambule. The network helps show where Ivan Mambule may publish in the future.

Co-authorship network of co-authors of Ivan Mambule

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Mambule. A scholar is included among the top collaborators of Ivan Mambule based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Mambule. Ivan Mambule is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kityo, Cissy, Ivan Mambule, Simiso Sokhela, et al.. (2025). Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial. Nature Medicine. 32(1). 168–177.

Mathieson, Sean, Eleanor Duckworth, Ivan Mambule, et al.. (2024). Retrospective characterization of seizure semiology and treatment using continuous video‐EEG monitoring in neonatal encephalopathy in Uganda. Epileptic Disorders. 27(1). 31–43. 1 indexed citations

Mambule, Ivan, Jonathan M. Read, Anmol Kiran, et al.. (2024). Epidemiology of Human Seasonal Coronaviruses Among People With Mild and Severe Acute Respiratory Illness in Blantyre, Malawi, 2011–2017. The Journal of Infectious Diseases. 230(2). e363–e373. 3 indexed citations

Mathieson, Sean, Annettee Nakimuli, Vicki Livingstone, et al.. (2024). EEG background activity, seizure burden and early childhood outcomes in neonatal encephalopathy in Uganda: a prospective feasibility cohort study. EClinicalMedicine. 78. 102937–102937. 1 indexed citations

Kityo, Cissy, Ivan Mambule, Simiso Sokhela, et al.. (2024). Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. The Lancet Infectious Diseases. 24(10). 1083–1092. 47 indexed citations breakdown →

Mambule, Ivan, Loice Achieng Ombajo, Simiso Sokhela, et al.. (2024). Two-drug regimens for the treatment of HIV in Africa. The Lancet HIV. 11(6). e419–e426. 3 indexed citations

Medvedev, Melissa M., Giulia Greco, Ivan Mambule, et al.. (2023). Process and costs for readiness to safely implement immediate kangaroo mother care: a mixed methods evaluation from the OMWaNA trial at five hospitals in Uganda. BMC Health Services Research. 23(1). 613–613. 4 indexed citations

Tam, Pui‐Ying Iroh, James Chirombo, Marc Henrion, et al.. (2022). Clinical pneumonia in the hospitalised child in Malawi in the post-pneumococcal conjugate vaccine era: a prospective hospital-based observational study. BMJ Open. 12(2). e050188–e050188. 2 indexed citations

Medvedev, Melissa M., Ivan Mambule, Cally J Tann, et al.. (2020). Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial to examine mortality impact in Uganda. Trials. 21(1). 126–126. 16 indexed citations

10.

Kiwuwa-Muyingo, Sylvia, George Abongomera, Ivan Mambule, et al.. (2019). Lessons for test and treat in an antiretroviral programme after decentralisation in Uganda: a retrospective analysis of outcomes in public healthcare facilities within the Lablite project. International Health. 12(5). 429–443. 4 indexed citations

11.

Gooding, Kate, et al.. (2019). Dust or disease? Perceptions of influenza in rural Southern Malawi. PLoS ONE. 14(4). e0208155–e0208155. 3 indexed citations

12.

Kityo, Cissy, JA Thompson, Immaculate Nankya, et al.. (2017). HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 75(2). e45–e54. 22 indexed citations

13.

Wanyama, J, Bonnie Wandera, Agnes Kiragga, et al.. (2017). Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe–Africa Research Network for the Evaluation of Second-line Therapy trial. International Journal of STD & AIDS. 29(3). 287–297. 3 indexed citations

14.

Kiwuwa-Muyingo, Sylvia, Bernard Kikaire, Ivan Mambule, et al.. (2014). Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial. AIDS. 28(17). 2579–2588. 11 indexed citations

15.

Laker, Eva, et al.. (2014). Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala. Journal of the International AIDS Society. 17(4S3). 19792–19792. 5 indexed citations

16.

Kityo, Cissy, Diana M. Gibb, Charles F. Gilks, et al.. (2014). High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial. PLoS ONE. 9(3). e90772–e90772. 9 indexed citations

17.

Kiwuwa-Muyingo, Sylvia, Hannu Oja, A. Sarah Walker, et al.. (2013). Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality. BMC Infectious Diseases. 13(395). 1–14. 13 indexed citations

18.

Gilks, Charles F., A Sarah Walker, David Dunn, et al.. (2012). Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara). Antiviral Therapy. 17(7). 1363–1373. 14 indexed citations

19.

Stöhr, Wolfgang, Andrew Reid, A. Sarah Walker, et al.. (2011). Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa. Antiviral Therapy. 16(7). 1011–1020. 30 indexed citations

20.

Munderi, Paula, A. Sarah Walker, C. Kityo, et al.. (2010). Immune restoration over 5 years on ART among patients initiating treatment with advanced immune deficiency in the DART trial in Uganda and Zimbabwe..

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact